Posted by Michael Wonder on 20 Dec 2025
European Commission approves Tremfya (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
19 December 2025 - The decision is supported by the Phase 3 PROTOSTAR study, where guselkumab demonstrated higher levels of skin clearance versus placebo at week 16.
Johnson & Johnson today announced that the European Commission has extended the marketing authorisation for Tremfya (guselkumab) as a subcutaneous treatment to treat moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.
